Share on StockTwits

NxStage Medical (NASDAQ:NXTM) SVP Winifred L. Swan sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $13.46, for a total value of $26,920.00. Following the sale, the senior vice president now directly owns 20,688 shares in the company, valued at approximately $278,460. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of NxStage Medical (NASDAQ:NXTM) traded up 0.15% on Tuesday, hitting $13.56. 155,338 shares of the company’s stock traded hands. NxStage Medical has a one year low of $8.77 and a one year high of $15.00. The stock’s 50-day moving average is $13.91 and its 200-day moving average is $13.16. The company’s market cap is $832.8 million.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. On average, analysts predict that NxStage Medical will post $-0.40 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of NxStage Medical from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 2nd. They now have a $15.60 price target on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $16.77.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.